ERBB2 and triple-negative breast carcinoma: To our knowledge, the study by Nakai M et al. is the only one analyzing EV-DNA in breast cancer, with a heterogeneous and limited number of samples across the three molecular subtypes (luminal, HER2+, and triple-negative breast cancer) [35].